Get the Stockscreener App
17.27
2.69%
0.49
10 X Genomics Inc stock is traded at $17.27, with a volume of 477.99K.
It is up +2.69% in the last 24 hours and down -13.93% over the past month.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
See More
Previous Close:
$16.78
Open:
$16.47
24h Volume:
477.99K
Relative Volume:
0.27
Market Cap:
$2.05B
Revenue:
$631.73M
Net Income/Loss:
$-239.78M
P/E Ratio:
-9.0419
EPS:
-1.91
Net Cash Flow:
$-33.45M
1W Performance:
+9.13%
1M Performance:
-13.93%
6M Performance:
-37.29%
1Y Performance:
-56.62%
1-Day Range:
$16.35
$17.25
1-Week Range:
$15.02
$17.25
52-Week Range:
$14.02
$57.90
10 X Genomics Inc Stock (TXG) Company Profile
Name
10 X Genomics Inc
Sector
Industry
Phone
(925) 401-7300
Address
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-10-23 | Initiated | Barclays | Overweight |
| Mar-31-23 | Initiated | Stephens | Overweight |
| Feb-02-23 | Initiated | UBS | Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Aug-18-22 | Downgrade | Goldman | Neutral → Sell |
| Jul-25-22 | Initiated | Canaccord Genuity | Buy |
| Jul-15-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-14-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-15-21 | Initiated | William Blair | Outperform |
| Dec-02-20 | Initiated | Goldman | Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jul-10-20 | Initiated | Stifel | Buy |
| Mar-05-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-07-19 | Initiated | BofA/Merrill | Buy |
| Oct-07-19 | Initiated | Cowen | Outperform |
| Oct-07-19 | Initiated | JP Morgan | Overweight |
| Sep-24-19 | Initiated | Evercore ISI | Outperform |
View All
10 X Genomics Inc Stock (TXG) Latest News
10x Genomics Inc (TXG) Trading 2.45% Higher on Nov 4 - GuruFocus.com
10x Genomics (NASDAQ:TXG) Price Target Cut to $19.00 by Analysts at Barclays - MarketBeat
Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts - Simply Wall St
FY2024 EPS Estimates for 10x Genomics Boosted by Analyst - MarketBeat
Allspring Global Investments Holdings LLC Has $880,000 Stake in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative - PR Newswire
10x Genomics, Inc. (NASDAQ:TXG) Q3 2024 Earnings Call Transcript - Insider Monkey
TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative – Company Announcement - Financial Times
10x Genomics Inc (TXG) Q3 2024 Earnings Call Highlights: Navigat - GuruFocus.com
These Analysts Boost Their Forecasts On 10x Genomics After Q3 Results - Benzinga
10x Genomics Inc (TXG) Trading 4.91% Higher on Oct 30 - GuruFocus.com
UBS Group Lowers 10x Genomics (NASDAQ:TXG) Price Target to $20.00 - MarketBeat
10x Genomics (NASDAQ:TXG) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
10x Genomics Inc (TXG) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic ... - Yahoo Finance
10x Genomics: Q3 Earnings Snapshot - The Advocate
10x Genomics (TXG) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
10x Genomics falls 7% on 2024 revenue guidance cut - MSN
10x Genomics (TXG) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
10x Genomics Inc Reports Q3 2024 Revenue of $151.7 Million, Missing Estimates; Gross Margin Improves to 70% - GuruFocus.com
10x Genomics shares sink 7% on revenue miss, lowered outlook - Investing.com India
10x Genomics shares sink 7% on revenue miss, lowered outlook By Investing.com - Investing.com UK
10x Genomics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2024 - Marketscreener.com
10x Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
10x Genomics Reports Third Quarter 2024 Financial Results – Company Announcement - Financial Times
Zacks Industry Outlook Medical Systems, 10x Genomics and Omnicell - Yahoo Finance
10X Genomics' SWOT analysis: stock faces headwinds amid strong consumables demand - Investing.com India
Lecap Asset Management Ltd. Purchases Shares of 38,829 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics (TXG) Upgraded to Strong Buy: Here's Why - Yahoo Finance
PacBio Onso™ Short Read Sequencing Instrument Joins 10x Genomics Compatible Partner Program - StockTitan
10x Genomics (TXG) Set to Announce Earnings on Tuesday - MarketBeat
Morgan Stanley spotlights 10 small-cap stocks with at least 50% upside - Kursiv Media
10x Genomics Inc.: How Are They Adapting to Market Conditions & Customer Needs?Major Drivers - Smartkarma
European Unified Patent Court Rules in Favor of Bruker and NanoString, Invalidating Patent Asserted By 10x Genomics against NanoString’s CosMx SMI Products - Yahoo Finance
Analysts Set 10x Genomics, Inc. (NASDAQ:TXG) Target Price at $30.60 - MarketBeat
SG Americas Securities LLC Sells 77,766 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics Delivers 'Single Cell for a Single Cent' with New Chromium Launches - PR Newswire
Barclays Lowers 10x Genomics (NASDAQ:TXG) Price Target to $21.00 - MarketBeat
10x Genomics, Inc. to Post Q3 2024 Earnings of ($0.31) Per Share, Leerink Partnrs Forecasts (NASDAQ:TXG) - MarketBeat
10x Genomics Stock: Deciphering The Preliminary Q3 Earnings (NASDAQ:TXG) - Seeking Alpha
The Price Is Right For 10x Genomics, Inc. (NASDAQ:TXG) Even After Diving 28% - Simply Wall St
10X Genomics stock hits 52-week low at $14.91 amid market shifts - Investing.com India
10x Genomics reports dip in Q3 instrument sales, growth in consumables By Investing.com - Investing.com Australia
These Stocks Are Moving the Most Today: Tesla, Super Micro, AMD, and More - Barron's
10x Genomics reports dip in Q3 instrument sales, growth in consumables - Investing.com India
Where 10x Genomics Stands With Analysts - Benzinga
10x Genomics' (TXG) Overweight Rating Reiterated at Stephens - MarketBeat
10x Genomics (NASDAQ:TXG) PT Lowered to $20.00 - MarketBeat
10x Genomics (NASDAQ:TXG) Reaches New 1-Year LowShould You Sell? - MarketBeat
10X Genomics stock hits 52-week low at $14.91 amid market shifts By Investing.com - Investing.com South Africa
Tesla, Delta, Super Micro, 10x Genomics, Domino’s, TD Bank, and More Stock Movers - Barron's
Gene Sequencing Tech Provider 10x Genomics' Q3 Sales Fall Short On Expectations, But CEO Sees Opportunity Ahead - Benzinga
10 X Genomics Inc Stock (TXG) Financials Data
Revenue
Net Income
Cash Flow
EPS
10 X Genomics Inc Stock (TXG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hindson Benjamin J. | See Remarks |
Aug 22 '24 |
Sale |
22.53 |
4,351 |
98,027 |
345,704 |
| McAnear Justin J. | Former Chief Financial Officer |
Aug 22 '24 |
Sale |
22.53 |
2,961 |
66,710 |
143,242 |
0.73%
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):